# HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial

> **NCT04391231** · PHASE4 · WITHDRAWN · sponsor: **Cedars-Sinai Medical Center**

## Conditions studied

- Hemolysis Intravascular
- Acute Decompensated Heart Failure

## Interventions

- **DRUG:** Pentoxifylline Oral Product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04391231
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Initially the study was underfunded; then, the device we planned to use was changed and the new pump significantly reduced hemolysis.
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391231, "HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04391231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*